PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706

Primary outcome measure: change from baseline in sum of MDS-UPDRS parts 2 and 3

Secondary outcome measures: time from baseline to initiation of symptomatic medication, change in health related QOL